New CBO Scores May Boost Chances For Drug Patent Bills In Year-End Spending Package

By Gabrielle Wanneh / June 21, 2024 at 1:34 PM

A bill that aims to curb product hopping, patent thickets and other tactics brand drug makers use to delay generic and biosimilar market entry is now projected to save the government roughly $3 billion, nearly $2 billion more than what the Congressional Budget Office (CBO) projected back in 2022.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.